CHRISTUS launches revolutionary treatment for atrial fibrillation in Longview

CHRISTUS Heart and Vascular Institute – Longview has become the first Longview-area facility to use FARAPULSE™ pulsed field ablation (PFA) technology to treat patients with atrial fibrillation (AFib).

Atrial fibrillation is a serious condition that affects the heart's rhythm, causing it to beat irregularly and increasing the risk of heart failure and stroke. It is estimated that by 2030, more than 12 million Americans will be living with AFib.

The first procedure using the new system was performed at CHRISTUS Good Shepherd in July 2024, marking an important milestone in expanding access to advanced heart rhythm care for East Texas patients.

Pulsed field ablation represents a significant advancement in the treatment of atrial fibrillation and further strengthens CHRISTUS Good Shepherd's commitment to providing leading-edge cardiovascular care close to home.

Ablation is a common procedure used to treat atrial fibrillation. During the procedure, a small catheter is guided through a blood vessel to the heart to target the area responsible for the abnormal heart rhythm. Traditionally, ablation procedures have used extreme heat or extreme cold to achieve the desired therapeutic effect.

Research has shown that thermal ablation methods may carry risks to nearby structures, including the esophagus and phrenic nerve.

Pulsed field ablation uses a different approach that may help minimize damage to surrounding tissue while effectively treating abnormal heart rhythms. The technology can also improve procedural efficiency and support a positive patient experience.

Through a process known as electroporation, pulsed field ablation creates a therapeutic electric field using a purpose-built catheter positioned inside the heart. Tissue targeted for ablation is rendered electrically inactive while helping preserve surrounding structures.

The FARAPULSE™ PFA system received U.S. Food and Drug Administration approval on Jan. 31, expanding treatment options for patients with atrial fibrillation.

As one of the most common heart rhythm disorders, atrial fibrillation affects millions of Americans each year. By offering pulsed field ablation technology, CHRISTUS Good Shepherd continues to invest in advanced cardiovascular treatments designed to deliver high-quality care and improved outcomes for patients across the region.

To learn more about cardiovascular services available through CHRISTUS Health, visit Heart & Vascular Care | CHRISTUS Health.